Literature DB >> 20370437

A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea.

Young Kyoung Park1, Gyu Hong Lee, Jin Yang Baek, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song, Kwan Soo Ko.   

Abstract

We investigated the characteristics of a total of 96 Acinetobacter spp. isolates that were shown to cause bacteremia and urinary tract infections (UTIs) from 10 university hospitals located in various regions of Korea from November 2006 to August 2007. The antimicrobial susceptibilities of these isolates were determined using a broth microdilution method, and the species were identified using molecular identification. In addition, we performed multilocus sequence typing for Acinetobacter baumannii subgroup A isolates. A. baumannii subgroup A was the most prevalent in patients with both bacteremia (32 isolates, 53.3%) and UTIs (20 isolates, 55.6%), followed by Acinetobacter genomic species 13TU (15.0% and 27.8% in bacteremia and UTIs, respectively). A. baumannii subgroup B and Acinetobacter junii were found exclusively in isolates causing bacteremia (seven and five isolates, respectively). Among 96 Acinetobacter spp. isolates, 19.8% were resistant to imipenem and 25.0% were resistant to meropenem. Most carbapenem-resistant A. baumannii isolates contained PER or oxacillinase-23-like enzymes (65.2% and 78.3%, respectively). In addition, 13.5% were resistant to polymyxin B and 17.7% were resistant to colistin. A. baumannii subgroup A isolates (52 isolates, 54.2%) showed higher resistance rates to most antimicrobial agents than other species, but not to colistin. Among A. baumannii subgroup A isolates, ST22 was the most prevalent genotype (33 isolates, 63.5%) and showed higher resistance rates to all antimicrobial agents than the other genotypes. In addition, four out of five polymyxin-resistant A. baumannii group A isolates belonged to ST22. Thus, dissemination of the main clone of A. baumannii, ST22, may contribute to the high resistance rates of Acinetobacter isolates to antimicrobials, including carbapenems, in Korea.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370437     DOI: 10.1089/mdr.2009.0088

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  8 in total

1.  Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States.

Authors:  Jennifer M Adams-Haduch; Ezenwa O Onuoha; Tatiana Bogdanovich; Guo-Bao Tian; Jonas Marschall; Carl M Urban; Brad J Spellberg; Diane Rhee; Diane C Halstead; Anthony W Pasculle; Yohei Doi
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

2.  Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamine.

Authors:  Rebekah Henry; Nuwan Vithanage; Paul Harrison; Torsten Seemann; Scott Coutts; Jennifer H Moffatt; Roger L Nation; Jian Li; Marina Harper; Ben Adler; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

3.  Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in mice.

Authors:  Jaeyeong Park; Eunkyoung Shin; Ji-Hyun Yeom; Younkyung Choi; Minju Joo; Minho Lee; Je Hyeong Kim; Jeehyeon Bae; Kangseok Lee
Journal:  J Microbiol       Date:  2021-12-29       Impact factor: 3.422

4.  Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands.

Authors:  Dae Hun Kim; Ji-Young Choi; Hae Won Kim; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Visanu Thamlikitkul; Thomas Man-Kit So; Rohani M D Yasin; Po-Ren Hsueh; Celia C Carlos; Li Yang Hsu; Latre Buntaran; M K Lalitha; Jae-Hoon Song; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

5.  Bacteremia caused by Acinetobacter junii at a medical center in Taiwan, 2000-2010.

Authors:  H-Y Tsai; A Cheng; C-Y Liu; Y-T Huang; Y-C Lee; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-06       Impact factor: 3.267

6.  Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Antonio Moreno; Nathalie Fernández; Juán A Vallejo; Jesús Aranda; Ben Adler; Marina Harper; John D Boyce; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

7.  Molecular and epidemiological characterization of carbapenem-resistant Acinetobacter baumannii in non-tertiary Korean hospitals.

Authors:  Sunok Park; Hwa-Su Kim; Kyeong Min Lee; Jung Sik Yoo; Jae Il Yoo; Yeong Seon Lee; Gyung Tae Chung
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

Review 8.  Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot.

Authors:  Jocelyn Qi Min Teo; Yiying Cai; Tze-Peng Lim; Thuan Tong Tan; Andrea Lay-Hoon Kwa
Journal:  Microorganisms       Date:  2016-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.